Rizatriptan
Maxalt, Maxalt-mlt (rizatriptan) is a small molecule pharmaceutical. Rizatriptan was first approved as Maxalt on 1998-06-29. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1F, and 5-hydroxytryptamine receptor 1A.
| Trade Name | Maxalt, Maxalt-mlt |
|---|---|
| Common Name | Rizatriptan |
| Indication | migraine disorders |
| Drug Class | Antimigraine agents (5-HT1 receptor agonists),sumatriptan derivatives |
